Stockreport

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics, Inc.  (ATXS) 
PDF -- BioCryst’s Acquisition of Astria Expected to Close in the First Quarter of 2026 ---- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with Topline R [Read more]